Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
December 21 2016 - 8:30AM
Business Wire
Caforio will Succeed Lamberto Andreotti
Effective May 2, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the
company’s Board of Directors has appointed Giovanni Caforio, M.D.
as chairman of the board, effective May 2, the date of the
company’s annual meeting of shareholders. Caforio, who will
continue to serve as chief executive officer, will succeed current
Chairman Lamberto Andreotti, who has announced his plan to
retire.
“It is an honor to have the opportunity to build on the strong
foundation established by Lamberto Andreotti,” said Caforio.
“Bristol-Myers Squibb has tremendous opportunities for growth,
highlighted by our leadership position in Immuno-Oncology and the
opportunity to accelerate our diversified pipeline of
transformational medicines. Working with the talented leaders and
employees of this company, I look forward to further advancing our
BioPharma strategy, and delivering transformational medicines that
make a difference in the lives of patients around the world.”
“Since being named CEO, Giovanni has clearly demonstrated the
capabilities needed to lead Bristol-Myers Squibb in the near and
long term,” said Andreotti. “It was a pleasure working with
Giovanni during this transition period, and I have full confidence
that he will do what is needed to continue to deliver on the
company’s mission and generate sustainable growth for our
shareholders now and in the future.”
Togo D. West, Jr., the board’s lead independent director, said,
“Since becoming CEO last year, Giovanni has demonstrated strong
leadership and a commitment to the company’s patient-focused
mission and culture of integrity and ethics. Giovanni’s depth of
experience, knowledge and deep understanding of the industry make
him the right person for the chairmanship.”
“I also want to thank Lamberto for his many years of service to
the company and for serving as chairman. As a valued and trusted
leader, he played a critical role in the company’s transformation
to a BioPharma leader and in shaping the strategy that continues to
guide the company today.”
Andreotti served as Bristol-Myers Squibb’s chief executive
officer from 2010 through May 2015 and will have served as
Bristol-Myers Squibb’s chairman for two years when Caforio’s
appointment becomes effective in May 2017. Under Andreotti’s
leadership, Bristol-Myers Squibb successfully transformed into a
leader in the BioPharma industry, one known for its robust pipeline
and portfolio of innovative medicines, including the increasingly
promising portfolio of Immuno-Oncology medicines that are
transforming the treatment of cancer today.
Caforio has been chief executive officer of Bristol-Myers Squibb
since May 2015 and has been serving on the company’s Board of
Directors since June 2014. As CEO, Caforio has led the
company’s focus on researching and developing transformational
medicines, which includes a leading portfolio of immunotherapies
that are fundamentally changing the way patients live with cancer.
With a background as a physician, Caforio has helped strengthen the
company’s patient-focused culture -- one driven by innovation,
speed, accountability and passion.
Prior to becoming CEO, Caforio served as chief operating officer
with responsibility for leading a fully integrated worldwide
commercial organization and the companywide functions of Enterprise
Services and Global Manufacturing & Supply. This was
preceded by his work as the company’s chief commercial officer.
Born and educated in Italy, Caforio received his M.D. from the
University of Rome.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161221005388/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comLaura Hortas,
609-252-4587laura.hortas@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024